Inavolisib, palbociclib, fulvestrant combo shows sustained benefit beyond disease progression in HER2‑negative metastatic breast cancer

Looking at real world evidence on PSA testing in prostate cancer

Cabozantinib and atezolizumab show more efficacy compared to second NHT in patients with mCRPC

Enzalutamide monotherapy prolongs MFS compared to leuprolide alone in men with high-risk biochemically recurrent PC

CDK-4/6 inhibitors with endocrine treatment for metastatic breast cancer

Preoperative endocrine therapy in premenopausal women leads to sparing chemotherapy in additional patients

Cancer care in Needle Hospital, Hargeisa, Somaliland

Cabozantinib shows clinically meaningful improvement in advanced neuroendocrine tumours

Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervical cancer

CAR-T therapy and impact to cancer patient outcomes and experience of treatment

Pembrolizumab plus chemoradiotherapy shows clinically meaningful improvement in PFS for locally advanced cervical cancer

2 year recurrence free survival benefit for resectable melanoma treated with neoadjuvant/adjuvant pembrolizumab